Targeting specific proteins to improve treatment for glioblastoma
Official title: Generating Synthetic Lethality in Glioblastoma with a First-In-Class Non-Muscle Myosin II Inhibitor
Funded at Mayo Clinic Jacksonville · NIH-11016213 · Data updated 2026-11-12
This study is looking at a new drug that might help people with glioblastoma, a type of brain cancer, by working alongside current treatments like radiation to make them more effective and hopefully improve survival rates.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Jacksonville NIH-funded |
| Lab location | 1 site (Jacksonville, United States) |
| Project start | January 1, 2025 |
| Project end | December 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $607,634 |
| NIH project number | 1R01CA295558-01 |
| Project ID | NIH-11016213 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with glioblastoma who are seeking new treatment options.
✕Less likely to help
Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
What this research studies
This research investigates a new treatment approach for glioblastoma, a type of brain cancer, by using a novel drug that inhibits certain proteins involved in cancer cell movement and survival. The study aims to understand how this drug, combined with existing therapies, can enhance the effectiveness of treatments like radiation and other targeted therapies. By exploring the interactions between this drug and cancer signaling pathways, the researchers hope to improve patient outcomes and extend survival rates. The ultimate goal is to prepare for clinical trials that will test this treatment in humans.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with glioblastoma, potentially improving survival rates and quality of life.
How similar studies have gone: Previous research has shown promising results with similar approaches targeting cancer cell signaling and movement, indicating potential for success in this novel treatment.
Where this research is happening
-
Mayo Clinic Jacksonville
Jacksonville, United States Active
Researchers
- Principal investigator: Rosenfeld, Steven S — Mayo Clinic Jacksonville
- Study coordinator: Rosenfeld, Steven S
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.